Here are three things to know.
- The Parkinson’s drug levodopa can cause dyskinesia, or uncontrolled, involuntary movement.
- Gocovri is a once-daily drug intended to control levodopa-induced dyskinesia. The drugs main ingredient, amantadine, has been on the market for several decades as an antiviral drug.
- Adamas Pharmaceuticals expects the drug to be available in the fourth quarter of this year and formally launch in January 2018.
More articles on supply chain:
US Bioservices to pay $13.4M to resolve kickback suit
Samsung widens stake in prescription drug market through partnership with Japanese pharmaceutical company
Patients brace for price of ‘breakthrough’ leukemia drug CTL019
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.